ProShare Advisors
LRMR icon

ProShare Advisors’s Larimar Therapeutics LRMR Stock Holding History

ProShare Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Buy
12,125
+425
+4% +$1.69K ﹤0.01% 1871
2026
Q1 		$52.7K Sell
11,700
-923
-7% -$3.69K ﹤0.01% 1778
2025
Q4 		$48.1K Buy
12,623
+1,535
+14% +$5.97K ﹤0.01% 1959
2025
Q3 		$35.8K Buy
11,088
+18
+0.2% +$67 ﹤0.01% 1959
2025
Q2 		$32K Sell
11,070
-915
-8% -$2.12K ﹤0.01% 2036
2025
Q1 		$25.8K Sell
11,985
-2,885
-19% -$9.12K ﹤0.01% 2019
2024
Q4 		$57.5K Buy
+14,870
New +$98.2K ﹤0.01% 2161
2019
Q4 		– Sell
-843
Closed -$7K – 1795
2019
Q3 		$7K Sell
843
-334
-28% -$3.66K ﹤0.01% 1655
2019
Q2 		$17K Sell
1,177
-143
-11% -$3.81K ﹤0.01% 1613
2019
Q1 		$43K Buy
1,320
+11
+0.8% +$564 ﹤0.01% 1619
2018
Q4 		$78K Buy
+1,309
New +$129K ﹤0.01% 1500
2016
Q4 		– Sell
-1,624
Closed -$65K – 1747
2016
Q3 		$65K Sell
1,624
-301
-16% -$13.7K ﹤0.01% 1433
2016
Q2 		$138K Buy
1,925
+90
+5% +$7.11K ﹤0.01% 1488
2016
Q1 		$147K Sell
1,835
-190
-9% -$15K ﹤0.01% 1472
2015
Q4 		$153K Buy
2,025
+170
+9% +$27.3K ﹤0.01% 1596
2015
Q3 		$711K Sell
1,855
-109
-6% -$49.1K 0.01% 793
2015
Q2 		$816K Buy
1,964
+81
+4% +$33.9K 0.01% 863
2015
Q1 		$895K Buy
1,883
+507
+37% +$241K 0.01% 894
2014
Q4 		$509K Buy
+1,376
New +$355K 0.01% 1190

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

ProShare Advisors's LRMR Position: Q2 2026 in Review

ProShare Advisors increased its Larimar Therapeutics (LRMR) stake by 3.6% in Q2 2026, buying an estimated $1.69K and bringing the position to 12,125 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

ProShare Advisors first reported a position in LRMR in Q4 2014 and has held it in 19 quarters since. The position peaked at $895K in Q1 2015. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • ProShare Advisors held 12,125 shares of Larimar Therapeutics worth $37K as of Q2 2026.
  • ProShare Advisors bought 425 Larimar Therapeutics shares in Q2 2026, an estimated $1.69K.
  • Larimar Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1871 holding.
  • ProShare Advisors first reported a position in Larimar Therapeutics in Q4 2014 and has held it in 19 quarters since.
  • ProShare Advisors's Larimar Therapeutics position peaked at $895K in Q1 2015.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.